Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835396 | 0.90 | MRGPRX4 (0.37) | PARK7KMT2AHPGDMEN1KDM4E | |
| SCHEMBL6831719 | 0.89 | NR4A2 (0.39) | PARK7KMT2AHPGDMEN1NR1H2 | |
| SCHEMBL6835323 | 0.89 | RXRA (0.39) | PARK7KMT2AHPGDMEN1ALDH1A1 | |
| SCHEMBL6669286 | 0.87 | ALDH1A1 (0.54) | KMT2AHPGDMEN1L3MBTL1ALDH1A1 | |
| SCHEMBL6831808 | 0.86 | HTR7 (0.36) | PARK7NR1H2NR1H3L3MBTL1KDM4E | |
| SCHEMBL6831758 | 0.86 | TSHR (0.39) | PARK7NR1H2NR1H3KDM4EPOLB | |
| SCHEMBL6835226 | 0.83 | KDM5A (0.36) | PARK7 | |
| SCHEMBL6681605 | 0.81 | DRD2 (0.49) | KMT2AMEN1ALDH1A1POLB | |
| SCHEMBL6678968 | 0.75 | NR1H2 (0.49) | PARK7KMT2AHPGDMEN1NR1H2 | |
| SCHEMBL6835596 | 0.75 | DRD2 (0.45) | KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | HICKS JAMES LESTER (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP26, MMP9 | PARK7 639/4885KMT2A 2806/4885HPGD 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.